Skip to main content

[]

Intended for healthcare professionals
Skip to main content
Restricted access
Research article
First published online September 10, 2019

Treatment of Mycoplasma pneumoniae-Induced Rash and Mucositis With Cyclosporine

Heidi Oi-Yee Li https://orcid.org/0000-0001-6495-088X, Sophia Colantonio, and Michele L. Ramien https://orcid.org/0000-0001-9191-3611 [email protected]View all authors and affiliations
Volume 23, Issue 6
https://doi.org/10.1177/1203475419874444

Abstract

Background

Mycoplasma pneumoniae-induced rash and mucositis (MIRM) is a relatively newly recognized clinical entity that typically presents with predominant mucositis accompanied by variable cutaneous involvement 7-9 days after the onset of prodromal symptoms. There are no evidence-based guidelines for treatment, and current standards of care may include supportive therapy, antibiotics, corticosteroids, and intravenous immunoglobulin .

Objective

This case series aims to describe the potential efficacy of cyclosporine A (CsA) in the treatment of MIRM.

Methods

The present case series details our use of CsA early in the course of MIRM in 3 pediatric patients.

Results

Rapid clinical resolution was observed following CsA therapy.

Conclusions

We suggest that early initiation of CsA may be an effective therapeutic option for MIRM.

Get full access to this article

View all access and purchase options for this article.

Get Access

References

1. Sánchez-Vargas FM, Gómez-Duarte OG. Mycoplasma pneumoniae-an emerging extra-pulmonary pathogen. Clin Microbiol Infect. 2008;14(2):105-117.
Crossref
Google Scholar
2. Narita M. Classification of extrapulmonary manifestations due to Mycoplasma pneumoniae infection on the basis of possible pathogenesis. Front Microbiol. 2016;7:23.
Crossref
Google Scholar
3. Canavan TN, Mathes EF, Frieden I, Shinkai K. Mycoplasma pneumoniae-induced rash and mucositis as a syndrome distinct from Stevens-Johnson syndrome and erythema multiforme: a systematic review. J Am Acad Dermatol. 2015;72(2):239-245.
Crossref
Google Scholar
4. Gilbert M, Scherrer LA. Efficacy and safety of cyclosporine in Stevens-Johnson syndrome and toxic epidermal necrolysis. Dermatol Ther. 2018;32(1):e12758.
Crossref
Google Scholar
5. Chaudhry R, Ghosh A, Chandolia A. Pathogenesis of Mycoplasma pneumoniae: an update. Indian J Med Microbiol. 2016;34(1):7-16.
Crossref
Google Scholar
6. Waites KB, Talkington DF. Mycoplasma pneumoniae and its role as a human pathogen. Clin Microbiol Rev. 2004;17(4):697–728.
Crossref
Google Scholar
7. Meyer Sauteur PM, Goetschel P, Lautenschlager S. Mycoplasma pneumoniae and mucositis–part of the Stevens-Johnson syndrome spectrum. J Dtsch Dermatol Ges. 2012;10(10):740-746.
Crossref
Google Scholar
8. Vujic I, Shroff A, Grzelka M, et al. Mycoplasma pneumoniae-associated mucositis–case report and systematic review of literature. J Eur Acad Dermatol Venereol. 2015;29(3):595-598.
Crossref
Google Scholar
9. Michaels B. The role of systemic corticosteroid therapy in erythema multiforme major and Stevens-Johnson syndrome: a review of past and current opinions. J Clin Aesthet Dermatol. 2009;2(3):51-55.
Google Scholar
10. Zipitis CS, Thalange N. Intravenous immunoglobulins for the management of Stevens-Johnson syndrome with minimal skin manifestations. Eur J Pediatr. 2007;166(6):585-588.
Crossref
Google Scholar
11. Amor KT, Ryan C, Menter A. The use of cyclosporine in dermatology: part I. J Am Acad Dermatol. 2010;63(6):925–946.
Crossref
Google Scholar
12. Gardiner SJ, Gavranich JB, Chang AB; Cochrane Acute Respiratory Infections Group. Antibiotics for community-acquired lower respiratory tract infections secondary to Mycoplasma pneumoniae in children. Cochrane Database Syst Rev. 2015;1(5):CD004875.
Crossref
Google Scholar
13. Bhutani T, Lee CS, Koo JYM. Cyclosporine. In: Wolverton SE, Arlook T, eds. Comprehensive Dermatologic Drug Therapy. 3rd ed. Toronto:Saunders/Elsevier; 2013:199-211.
Google Scholar
14. Waites KB, Xiao L, Liu Y, Balish MF, Atkinson TP. Mycoplasma pneumoniae from the respiratory tract and beyond. Clin Microbiol Rev. 2017;30(3):747-809.
Crossref
Google Scholar
15. Todd SR, Dahlgren FS, Traeger MS, et al. No visible dental staining in children treated with doxycycline for suspected Rocky Mountain spotted fever. J Pediatr. 2015;166(5):1246-1251.
Crossref
Google Scholar
16. Pöyhönen H, Nurmi M, Peltola V, Alaluusua S, Ruuskanen O, Lähdesmäki T. Dental staining after doxycycline use in children. J Antimicrob Chemother. 2017;72(10):2887-2890.
Crossref
Google Scholar

Supplementary Material

Please find the following supplemental material available below.

For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.

For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.

Supplemental Material

Treatment of Mycoplasma pneumoniae-Induced Rash and Mucositis With Cyclosporine

Cite article

Cite article

Cite article

OR

Download to reference manager

If you have citation software installed, you can download article citation data to the citation manager of your choice

Share options

Share

Share this article

Share with email
Email Article Link
Share on social media

Share access to this article

Sharing links are not relevant where the article is open access and not available if you do not have a subscription.

For more information view the Sage Journals article sharing page.

Information, rights and permissions

Information

Published In

Volume 23, Issue 6
Pages: 608 - 612
Article first published online: September 10, 2019
Issue published: November/December 2019

Keywords

  1. case series
  2. cyclosporine
  3. cyclosporine A
  4. Fuchs syndrome
  5. MIRM
  6. Mycoplasma pneumoniae-induced rash and mucositis
  7. mucositis
  8. mycoplasma
  9. Mycoplasma pneumoniae-associated mucositis
  10. MPAM
  11. pediatric
  12. Stevens-Johnson syndrome
  13. SJS
  14. therapeutics

Rights and permissions

© The Author(s) 2019.
Request permissions for this article.
PubMed: 31502864

Authors

Affiliations

Heidi Oi-Yee Li*
Faculty of Medicine, University of Ottawa, Ontario, Canada
https://orcid.org/0000-0001-6495-088X
View all articles by this author
Sophia Colantonio*
Faculty of Medicine, University of Ottawa, Ontario, Canada
View all articles by this author
Michele L. Ramien
Division of Rheumatology and Dermatology, Children’s Hospital of Eastern Ontario, Ottawa, Canada
Division of Community Pediatrics, Alberta Children’s Hospital, Calgary, AB, Canada
https://orcid.org/0000-0001-9191-3611
[email protected]
View all articles by this author

Notes

Michele L. Ramien, Alberta Children’s Hospital, 28 Oki Drive NW, Calgary AB T3B 6A8, Canada. Email: [email protected]
*
These authors contributed equally to this work.

Metrics and citations

Metrics

Journals metrics

This article was published in Journal of Cutaneous Medicine and Surgery.

View All Journal Metrics

Article usage*

Total views and downloads: 1168

*Article usage tracking started in December 2016

Altmetric

See the impact this article is making through the number of times it’s been read, and the Altmetric Score.
Learn more about the Altmetric Scores


Articles citing this one

Receive email alerts when this article is cited

Web of Science: 17 view articles Opens in new tab

Crossref: 25

  1. Unique Presentation of Mycoplasma pneumoniae-Induced Rash and Mucositis with Salivary Gland Inflammation in a Pediatric Patient: A Case Report
    Go to citationCrossrefGoogle Scholar
  2. Cyclosporin als Erstlinienbehandlung bei SARS‐CoV‐2‐reaktiver infektiöser mukokutaner Eruption bei Erwachsenen
    Go to citationCrossrefGoogle Scholar
  3. Reactive Infectious Mucocutaneous Eruption with Extensive Cutaneous Involvement
    Go to citationCrossrefGoogle Scholar
  4. SARS‐CoV‐2 reactive infectious mucocutaneous eruptions in adults treated with cyclosporine as first line treatment
    Go to citationCrossrefGoogle Scholar
  5. Recurrent Reactive Infectious Mucocutaneous Eruption in an Adult Male Secondary to Mycoplasma Infection: A Case Report
    Go to citationCrossrefGoogle Scholar
  6. Rash from the past: A case of recurrent reactive infectious mucocutaneous eruption triggered by common coronavirus
    Go to citationCrossrefGoogle Scholar
  7. Clinical manifestations of skin and mucosal epithelium lesions in children with mycoplasma infection
    Go to citationCrossrefGoogle Scholar
  8. Mycoplasma pneumoniae-induced rash and mucositis: A rare extrapulmonary manifestation of mycoplasma pneumoniae infection
    Go to citationCrossrefGoogle Scholar
  9. Reactive infectious mucocutaneous eruption following COVID ‐19 in an adolescent boy: Case report and review of the literature
    Go to citationCrossrefGoogle Scholar
  10. Reactive infectious mucocutaneous eruption – repeat etanercept after intravenous immunoglobulin: A case report
    Go to citationCrossrefGoogle ScholarPub Med
  11. View More

Figures and tables

Figures & Media

Tables

View Options

Access options

If you have access to journal content via a personal subscription, university, library, employer or society, select from the options below:

CDA/ACD members can access this journal content using society membership credentials.

CDA Membership Login

ACD Membership Login

CDA/ACD members can access this journal content using society membership credentials.

CDA Membership Login

ACD Membership Login

Alternatively, view purchase options below:

Purchase 24 hour online access to view and download content.

Subscribe to this journal

Access journal content via a DeepDyve subscription or find out more about this option.

Start 2 week free trial
Need help?

View options

PDF/EPUB

View PDF/EPUB

Full Text

View Full Text
View full text|Download PDF

Also from Sage